Connect your AI

KLRS KLRS Operating lease liabilities

Operating lease liabilities at other companies

Ocular TherapeutixOCUL

——

Kodiak Sciences IncKOD

——

4D Molecular TherapeuticsFDMT

——

Rigel PharmaceuticalsRIGL

——

PVL

Palvella TherapeuticsPVLA

——

Other financials

Income statement

Operating income-$11.8M-14.3%

Net income-$10.9M-6.5%

EPS (diluted)-$0.46+81.7%

Balance sheet

Cash & equivalents$34.4M-65.9%

Total debt$1.4M—

Total equity$68.6M+7.3%

Total assets$109.8M+6.5%

Cash flow

Operating cash flow-$11.6M-55.6%

CapEx$17.0K—

Free cash flow-$7.1M—

Valuation

Market cap$96.83M+136%

Enterprise value$63.82M—

Returns & leverage

Return on equity-66.6%—

Debt / equity0×—

Current ratio12.2×-2.1×

Where this comes from

Reported directly by KLRS in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInOperatingLeaseLiability.

The official record: KLRS’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about KLRS's operating lease liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is KLRS's operating lease liabilities?: KLRS (KLRS) reported operating lease liabilities of -$37K in Q1 2026.